Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Gilead Sciences, Inc. trades at $134.65 (market cap $163.51B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.95. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| GILD | SJNK | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $25.63 |
52-Week Low | $108.22 | $24.75 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SJNK trades at $24.945, up 0.14% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains consistent monthly dividend distributions, including recent payments of $0.14 and $0.15 per share. Recent news highlights institutional accumulation by Berkshire Money Management but cautions on high-yield bond exposure amid economic uncertainty.
Outlook remains cautious due to bearish technical indicators and analyst skepticism about high-yield bond sustainability. Risks include interest rate sensitivity and credit spread volatility, while the dividend yield offers income appeal. Investors should weigh income stability against potential capital depreciation in a tightening cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
